Results for Beta Cell

Dr. Ackermann studies diabetes (types 1 and 2) and congenital hyperinsulinism using mouse models, cell lines, and primary human tissue. She aims to identify novel pathways regulating beta cell insulin secretion, leading to innovative therapeutic strategies for these disorders. Current studies include in vivo mouse physiology, ex vivo human islet physiology, CRISPR-Cas9 gene editing, epigenetic modification, and single-cell functional genomics.

Dr. Gadue studies cell fate decisions, focusing on endoderm and mesoderm specification using human embryonic stem (ES) cells and induced pluripotent stem (iPS).

Dr. Leavens uses stem cell-derived beta cells to model pediatric beta cell disease, including monogenic diabetes and congenital hyperinsulinism. The goal of her studies is to better understand and develop novel therapeutics to treat these diseases.

Dr. Samelson-Jones is a pediatric hematologist dedicated to improving the lives of children with bleeding and clotting disorders. His research focuses on gene therapy for hemophilia, the biochemical basis of coagulation, and the immune responses to hemophilia therapies.

Dr. Richman's research focuses on chimeric antigen receptor (CAR) T cells targeting solid tumors with the goal of translating these findings to this unmet clinical need.

Dr. Stanley’s lab has identified many of the genes and syndromes associated with congenital hyperinsulinism including ABCC8, GCK, GLUD1, and Turner and Beckwith syndromes. Working with clinical and rodent model studies, his lab team has identified distinctive phenotypes of these disorders, including diazoxide unresponsiveness, leucine sensitivity, and protein sensitivity. Dr. Stanley continues to seek new diagnostic and treatment paradigms for infants with acquired and genetic disorders of hyperinsulinism.

Dr. De Leon-Crutchlow’s translational research program focuses on examining the pathophysiology of disorders of insulin regulation, identifying novel therapeutic targets, and developing new therapies for these conditions. The program approach includes patient-oriented research and bench research employing mouse models and primary islet cultures.

Dr. Poncz investigates the megakaryocyte-platelet-thrombus axis. The process by which hematopoietic stem cells differentiate into megakaryocytes are the central foci of his laboratory work. Many of his studies focus on the biology and pathobiology of the platelet-specific proteins, chemokines Platelet Factor 4 (PF4)/Platelet Basic Protein (PBP) and the integrin alphaIIb/beta3 receptor.

Dr. Abdulmalik’s research interests involve hemoglobinopathies and red blood cell disorders, with a focus on sickle cell disease and beta-thalassemia.